Skip to main content
Home

BTK inhibitors in the treatment of B-cell lymphoma

WEBCAST WATCH NOW - Broadcast on the 17th December 2021

User Menu

  • HOME

 

Chaired by Dr Anthony Mato

Featuring Dr Deborah Stephens

Featuring Professor Martin Dreyling

Welcome to this expert-led webcast with global experts discussing Bruton's tyrosine kinase (BTK) inhibitors in the treatment of B-cell malignancies. 

This program reviews key data presented at the ASH 2021 Annual Meeting, highlighting the advances being made that have the potential to shape future patient care for people with mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). 

Audience 

This program is designed for, but not limited to, hematologists, oncologists, and other healthcare professionals involved in the management of patients with hematologic malignancies globally.

Learning objectives

After participating in the program, learners will be able to:

  1. Compare the efficacy and safety profiles of approved and emerging BTK inhibitors in the treatment of MCL, CLL and SLL
  2. Explain how these profiles inform current practice and could shape future patient care
  3. Incorporate BTK inhibitors in the clinical management of MCL, CLL and SLL 

Educational Grant 

This activity is supported by an educational grant from Lilly.

Accreditation

In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Springer Healthcare IME.

 

Primary tabs

  • Create new account
  • Log in
  • Reset your password
Enter your email address.
Enter the password that accompanies your email address.

This activity is supported by an educational grant from Lilly.

CONTACT US

IME@SPRINGER.COM
SPRINGER HEALTHCARE IME
THE CAMPUS, 4 CRINAN STREET
LONDON N1 9XW, UK

COPYRIGHT 2021. ALL RIGHTS RESERVED

Footer

  • Privacy Policy
  • Cookie Policy
  • Contact Technical Support
  • Terms and conditions

Paediatric Endocrinology

Springer Healthcare IME